Bio-Works Technologies (BIOWKS) Stock Overview
Engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BIOWKS Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bio-Works Technologies AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.60 |
| 52 Week High | SEK 3.56 |
| 52 Week Low | SEK 0.72 |
| Beta | 1.17 |
| 1 Month Change | 6.56% |
| 3 Month Change | -10.34% |
| 1 Year Change | 192.13% |
| 3 Year Change | -88.50% |
| 5 Year Change | -66.92% |
| Change since IPO | -79.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOWKS | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 8.3% | -3.4% | -1.8% |
| 1Y | 192.1% | -24.5% | 1.5% |
Return vs Industry: BIOWKS exceeded the Swedish Medical Equipment industry which returned -23.3% over the past year.
Return vs Market: BIOWKS exceeded the Swedish Market which returned 1.9% over the past year.
Price Volatility
| BIOWKS volatility | |
|---|---|
| BIOWKS Average Weekly Movement | 11.8% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: BIOWKS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BIOWKS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 29 | Lone Carlbom | www.bio-works.com |
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chromatography (IMAC) resin, size exclusion chromatography (SEC) resins, HTPD formats, screening kits, and desalting columns; and WorkBeads chromatography resins. Its products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications.
Bio-Works Technologies AB (publ) Fundamentals Summary
| BIOWKS fundamental statistics | |
|---|---|
| Market cap | SEK 255.39m |
| Earnings (TTM) | -SEK 29.78m |
| Revenue (TTM) | SEK 46.43m |
Is BIOWKS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOWKS income statement (TTM) | |
|---|---|
| Revenue | SEK 46.43m |
| Cost of Revenue | SEK 11.31m |
| Gross Profit | SEK 35.12m |
| Other Expenses | SEK 64.90m |
| Earnings | -SEK 29.78m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 75.64% |
| Net Profit Margin | -64.14% |
| Debt/Equity Ratio | 0% |
How did BIOWKS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 09:47 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Works Technologies AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.